• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Exagen Inc.

    5/20/25 4:43:58 PM ET
    $XGN
    Medical Specialities
    Health Care
    Get the next $XGN alert in real time by email
    S-8 1 exagen-formsx8registration.htm S-8 Document

    As filed with the Securities and Exchange Commission on May 20, 2025

    Registration No. 333-
     
      
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT UNDER
    THE SECURITIES ACT OF 1933  
    EXAGEN INC.
    (Exact name of registrant as specified in its charter)  
     
    Delaware  20-0434866
    (State or other jurisdiction of
    incorporation or organization)
      
    (I.R.S. Employer
    Identification No.)
    1261 Liberty Way
    Vista, California 92081
    (Address of principal executive offices) (Zip code)
    Exagen Inc. 2019 Incentive Award Plan
    Exagen Inc. 2019 Employee Stock Purchase Plan
    (Full title of the plans)
     
    John Aballi
    President and Chief Executive Officer
    Exagen Inc.
    1261 Liberty Way
    Vista, California 92081
    (760) 560-1501
    (Name, address, and telephone number, including area code, of agent for service)  
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
     
    Large accelerated filer☐Accelerated filer☐
    Non-accelerated filer☒Smaller reporting company☒
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐







    EXPLANATORY NOTE
    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the "SEC") for the purpose of registering an additional 882,016 shares of common stock of Exagen Inc. (the "Registrant") issuable or which may become issuable under the Exagen Inc. 2019 Incentive Award Plan (the "2019 Plan") and the Exagen Inc. 2019 Employee Stock Purchase Plan (the "2019 ESPP") pursuant to the evergreen provision of such plans.
    Pursuant to General Instruction E on Form S-8, the contents of the prior registration statements on Form S-8, File Nos. 333-233878, 333-256014, 333-264867, 333-272038 and 333-279356, previously filed with respect to the 2019 Plan and 2019 ESPP, are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"). These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.


    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    In this Registration Statement, Exagen Inc. is sometimes referred to as "Registrant," "we," "us" or "our."
    Item 3. Incorporation of Documents by Reference
    The Securities and Exchange Commission allows us to "incorporate by reference" the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents previously filed with the SEC:
    •The Registrant's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025, including the information incorporated by reference into our Annual Report on Form 10-K from our definitive proxy statement for our 2025 Annual Meeting of Stockholders, filed with the SEC on April 30, 2025;
    •The Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 5, 2025;
    •The Registrant's Current Reports on Form 8-K filed with the SEC on January 13, 2025, March 11, 2025, April 28, 2025, May 5, 2025, May 8, 2025 and May 9, 2025; and
    •The description of the Registrant's common stock set forth in the Registrant's registration statement on Form 8-A12B (Registration No. 001-39049), filed by the Registrant with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), on September 13, 2019, including any amendments or reports filed for the purpose of updating such description.



    In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this registration statement and to be a part hereof from the date of filing such documents, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement contained herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in any subsequently filed document which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
    Under no circumstances shall any information furnished under Item 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.





    EXHIBIT INDEX

    Incorporated by Reference
    Exhibit NumberExhibit DescriptionFormFile No.ExhibitExhibit Filing DateFiled/Furnished Herewith
    4.1
    Amended and Restated Certificate of Incorporation.
    8-K001-390493.19/23/2019
    4.2
    Amended Restated Bylaws.
    8-K001-390493.13/22/2021
    4.3
    Amendment to Amended and Restated Bylaws, dated January 19, 2023.
    8-K001-390493.11/23/2023
    4.4
    Specimen stock certificate evidencing the shares of common stock.
    S-1/A333-2334464.19/9/2019
    5.1
    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
    X
    23.1
    Consent of BDO USA, P.C., independent registered public accounting firm.
    X
    23.2
    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).
    X
    24.1
    Power of Attorney (see signature page)
    X
    99.1
    Exagen Inc. 2019 Incentive Award Plan.
    S-1/A333-23344610.39/9/2019
    99.2
    Form of Option Agreement under Exagen Inc. 2019 Incentive Award Plan.
    S-1/A333-23344610.49/9/2019
    99.3
    Form of Restricted Stock Unit Agreement under Exagen Inc. 2019 Incentive Award Plan.
    10-K001-3904910.53/16/2021
    99.4
    Exagen Inc. 2019 Employee Stock Purchase Plan.
    S-1/A333-23344610.59/9/2019
    107
    Filing Fee Table.
    X




    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Vista, State of California, on May 20, 2025.

    EXAGEN INC.
    by:/s/ John Aballi
    John Aballi
    President and Chief Executive Officer
    (Principal Executive Officer)

    POWER OF ATTORNEY

    Each person whose signature appears below hereby constitutes and appoints John Aballi and Jeffrey G. Black, and each of them singly (with full power to each of them to act alone), his attorneys-in-fact, each with the full power of substitution, for him in any and all capacities, to sign this registration statement, and any amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.




    SignatureTitleDate
    /s/ John AballiPresident, Chief Executive Officer and DirectorMay 20, 2025
    John Aballi(Principal Executive Officer)
    /s/ Jeffrey G. BlackChief Financial Officer and Corporate SecretaryMay 20, 2025
    Jeffrey G. Black(Principal Financial and Accounting Officer)
    /s/ Tina S. Nova, Ph.D.Executive Chairman of the Board of DirectorsMay 20, 2025
    Tina S. Nova, Ph.D.
    /s/ Ana HookerDirectorMay 20, 2025
    Ana Hooker
    /s/ Scott Kahn, Ph.D.DirectorMay 20, 2025
    Scott Kahn, Ph.D.
    /s/ Paul KimDirectorMay 20, 2025
    Paul Kim
    /s/ Bruce C. Robertson, Ph.D.DirectorMay 20, 2025
    Bruce C. Robertson, Ph.D.
    /s/ Frank StokesDirectorMay 20, 2025
    Frank Stokes

    Get the next $XGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XGN

    DatePrice TargetRatingAnalyst
    8/5/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    11/11/2021$33.00 → $30.00Overweight
    Keybanc
    10/15/2021$26.00Outperform
    Cowen
    More analyst ratings

    $XGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Nmsic Co-Investment Fund, L.P. sold $1,155,000 worth of shares (350,000 units at $3.30) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      3/27/25 4:15:57 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John was granted 8,621 shares, increasing direct ownership by 1% to 746,214 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      3/4/25 6:48:32 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Chief Financial Officer Black Jeffrey G. was granted 15,000 shares, increasing direct ownership by 5% to 289,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      2/25/25 8:59:29 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

      CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. All of the shares in the public offering, including the full exercise of the underwriter's option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting u

      5/9/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Prices Public Offering of Common Stock

      CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satis

      5/8/25 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Proposed Public Offering of Common Stock

      CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Exagen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Canac

      5/7/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    SEC Filings

    See more
    • SEC Form S-8 filed by Exagen Inc.

      S-8 - EXAGEN INC. (0001274737) (Filer)

      5/20/25 4:43:58 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Exagen Inc.

      8-K - EXAGEN INC. (0001274737) (Filer)

      5/9/25 4:05:59 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 424B5 filed by Exagen Inc.

      424B5 - EXAGEN INC. (0001274737) (Filer)

      5/8/25 4:08:47 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/19/24 7:24:38 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/18/24 6:32:33 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      5/16/24 8:02:50 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exagen downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Exagen from Overweight to Sector Weight

      8/5/22 9:00:50 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Keybanc reiterated coverage on Exagen with a new price target

      Keybanc reiterated coverage of Exagen with a rating of Overweight and set a new price target of $30.00 from $33.00 previously

      11/11/21 4:33:21 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Exagen with a new price target

      Cowen resumed coverage of Exagen with a rating of Outperform and set a new price target of $26.00

      10/15/21 7:34:02 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exagen Inc.

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      12/12/24 5:00:54 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 2:42:55 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 7:12:55 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Leadership Updates

    Live Leadership Updates

    See more

    $XGN
    Financials

    Live finance-specific insights

    See more
    • Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

      CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci

      8/1/24 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Changes to the Board of Directors

      CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief

      4/26/24 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Appoints Paul Kim to Board of Directors

      SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021, during the COVID-19 era. Mr. Kim has over 30 years working in accounting and finance, and over 15 years as a Chief Financial Officer of several public

      7/24/23 4:05:00 PM ET
      $FLGT
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

      CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.   Three Months Ended March 31,   2025   2024 (in thousands, except ASP data)  Revenue $15,498  $14,415 Gross margin  58.9%  59.6%Operating expenses $12,488  $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash and cash equivalents $11,194  $27,267 Trailing-twelve-month average selling price (ASP) $419  $377           Q1 2025 Highlights and Recent Corporate Updates: Delivered record total revenue of $15.5 million

      5/5/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

      CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

      4/21/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

      Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.   Three Months Ended December 31, Year Ended December 31,   2024   2024 (in thousands, except ASP data)  Revenue $13,655  $55,641 Gross margin  62.1%  59.5%Operating expenses $11,860  $46,748 Loss from operations $(3,383) $(13,636)Net los

      3/11/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care